Cova I, Di Battista M E, Vanacore N, Papi C P, Alampi G, Rubino A, Valente M, Meco G, Contri P, Di Pucchio A, Lacorte E, Priori A, Mariani C, Pomati S
Department of Clinical Sciences, Institute of Clinical Neurology, ASST Fatebenefratelli-Sacco, "Luigi Sacco" University Hospital, Milan, Italy.
Neurology Unit, Department of Health Sciences, ASST Santi Paolo e Carlo, "San Paolo" University Hospital, Milan, Italy.
Neurol Sci. 2017 Apr;38(4):673-678. doi: 10.1007/s10072-017-2830-z. Epub 2017 Feb 1.
Although non-motor symptoms (NMS) of Parkinson's disease (PD) are very common also in early stages of the disease, they are still under-recognized. Screening tools for non-motor symptoms, such as non-motor symptoms questionnaire (NMSQuest), help clinicians to recognize NMS and to evaluate if patients could require further assessment or specific treatments. To validate an adapted Italian version of NMSQuest and study its psychometric properties, Italian PD patients self-completed Italian NMSQuest, and then underwent a standard clinical evaluation including motor assessment (by Hoehn and Yahr staging, unified Parkinson's disease rating scale part III) and non-motor assessment (by Montreal cognitive assessment, Beck depression inventory, neuropsychiatric inventory, Epworth sleepiness scale, scale for outcomes in Parkinson's disease-Autonomic and movement disorder society-sponsored revision of the unified Parkinson's disease rating scale part I). Somatic comorbidities were quantified using the modified cumulative illness rating scale (CIRS). Seventy-one subjects were assessed (mean age years 69.8 ± 9.6 SD; 31% women; mean duration of disease 6.3 ± 4.6 years; H&Y median 2). Italian NMSQuest showed adequate satisfactory clinimetrics in terms of data quality, precision, acceptability, internal consistency and reliability. A significant correlation was found between NMSQuest and most of non-motor assessment scales, while no significant correlation appeared with motor severity as well as with age of patients, disease duration, levodopa equivalent daily dose, L-DOPA/dopamine agonists assumption and CIRS total score. The Italian version of the NMSQuest resulted as a reliable instrument for screening NMS in Italian PD patients.
尽管帕金森病（PD）的非运动症状（NMS）在疾病早期也非常常见，但它们仍未得到充分认识。非运动症状筛查工具，如非运动症状问卷（NMSQuest），有助于临床医生识别NMS并评估患者是否需要进一步评估或特定治疗。为了验证NMSQuest的意大利语改编版本并研究其心理测量特性，意大利PD患者自行完成意大利语NMSQuest，然后接受标准临床评估，包括运动评估（采用Hoehn和Yahr分期、统一帕金森病评定量表第三部分）和非运动评估（采用蒙特利尔认知评估、贝克抑郁量表、神经精神科问卷、爱泼华嗜睡量表、帕金森病自主神经和运动障碍协会赞助修订的统一帕金森病评定量表第一部分的结局量表）。使用改良的累积疾病评定量表（CIRS）对躯体合并症进行量化。对71名受试者进行了评估（平均年龄69.8±9.6岁；31%为女性；平均病程6.3±4.6年；H&Y中位数为2）。意大利语NMSQuest在数据质量、精度、可接受性、内部一致性和可靠性方面显示出足够令人满意的临床测量学特性。发现NMSQuest与大多数非运动评估量表之间存在显著相关性，而与运动严重程度以及患者年龄、病程、左旋多巴等效日剂量、左旋多巴/多巴胺激动剂使用情况和CIRS总分之间未出现显著相关性。NMSQuest的意大利语版本被证明是筛查意大利PD患者NMS的可靠工具。
